Trial
NCT01439542
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators
—
Condition
Prostate Cancer
Intervention
Stereotactic Body Radiation
Why stopped
Higher then expected Gr3 GU/GI toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-09